AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15142880 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-sequential induction (arm C)
Number of subjects: 592
Study 15142880 — intervention group
Group type: COMPARATOR
Intervention: Control '3 + 7' induction (arm A)
Number of subjects: 592
Study 12026533 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill ECG stress test (ST) in group A
Number of subjects: 59
Study 12026533 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of serum P-selectin levels in group B
Number of subjects: 59
Study 11699052 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 64
Study 11699052 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight subjects
Number of subjects: 64
Study 11699052 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (obese and normal-weight)
Number of subjects: 64
Study 11699052 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial state
Number of subjects: 64
Study 11699052 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma HDL-C concentration
Number of subjects: 64
Study 11699052 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial efflux
Number of subjects: 64
Study 9021439 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg tirilazad mesylate every 6 hours for 29 doses (6.0 mg/kg/day for 7 days)
Number of subjects: 18
Study 9021439 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg/kg tirilazad mesylate every 6 hours for 29 doses (12.0 mg/kg/day for 7 days)
Number of subjects: 18
Study 9021439 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg/kg tirilazad mesylate every 6 hours for 29 doses (16.0 mg/kg/day for 7 days)
Number of subjects: 18
Study 7950115 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofocal IOL (Pharmacia 720A)
Number of subjects: 84
Study 7950115 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOL (3M 825X)
Number of subjects: 84
Study 7950115 — intervention group
Group type: COMPARATOR
Intervention: Healthy phakic eyes (Control Group)
Number of subjects: 84
Study 2467136 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily
Number of subjects: 16
Study 2467136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1875538 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO 3708 (2.5 micrograms.kg‐1.min‐1 given with continuous infusion)
Number of subjects: 19
Study 1875538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1087137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate once per month with citrovorum rescue for 3 months
Number of subjects: 33
Study 1087137 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with a homogenate of Freund's complete adjuvant and soluble antigen derived from allogeneic lung cancer cells for 3 months
Number of subjects: 33
Study 1087137 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methotrexate and immunization monthly for 3 months
Number of subjects: 33
Study 1087137 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 33
Study 1087137 — intervention group
Group type: COMPARATOR
Intervention: Immunization
Number of subjects: 33
Study 1087137 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination immunochemotherapy
Number of subjects: 33
Study 30612246 — intervention group
Group type: EXPERIMENTAL
Intervention: ART restorations
Number of subjects: 154
Study 30612246 — intervention group
Group type: COMPARATOR
Intervention: Composite resin restorations
Number of subjects: 154
Study 27140481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport-specific drill training (MT)
Number of subjects: 20
Study 27140481 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (MT)
Number of subjects: 20
Study 27140481 — intervention group
Group type: COMPARATOR
Intervention: Sport-specific drill training alone (DT)
Number of subjects: 20
Study 27979834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin 2.5 mg/kg as an intravenous injection after anaesthesia induction but before start of surgery
Number of subjects: 150
Study 27979834 — intervention group
Group type: COMPARATOR
Intervention: Placebo as an intravenous injection after anaesthesia induction but before start of surgery
Number of subjects: 150
Study 27979834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin 2.5 mg/kg
Number of subjects: 150
Study 27979834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24332586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue strengthening programme paired with traditional exercises
Number of subjects: 0
Study 24332586 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercises alone
Number of subjects: 0
Study 21331635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment (60 s)
Number of subjects: 12
Study 21331635 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ozone treatment)
Number of subjects: 12
Study 19602718 — intervention group
Group type: EXPERIMENTAL
Intervention: TETA 100 mg
Number of subjects: 40
Study 19602718 — intervention group
Group type: EXPERIMENTAL
Intervention: TETA 300 mg
Number of subjects: 40
Study 19602718 — intervention group
Group type: EXPERIMENTAL
Intervention: TETA 600 mg
Number of subjects: 40
Study 19602718 — intervention group
Group type: EXPERIMENTAL
Intervention: TETA 1800 mg
Number of subjects: 40
Study 19602718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17469886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed feedback intervention
Number of subjects: 1488
Study 17469886 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 1488
Study 15280678 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bolus antithymocyte globulin (ATG)
Number of subjects: 0
Study 15280678 — intervention group
Group type: COMPARATOR
Intervention: Conventional cyclosporine triple therapy
Number of subjects: 0
Study 15280678 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell IgM FCXM
Number of subjects: 0
Study 12075256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 V
Number of subjects: 12
Study 12075256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 V
Number of subjects: 12
Study 12075256 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 V
Number of subjects: 12
Study 12075256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 V (with pacing thresholds of 0.5 V or less)
Number of subjects: 12
Study 12075256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 V (with pacing thresholds >0.5 V)
Number of subjects: 12
Study 12075256 — intervention group
Group type: COMPARATOR
Intervention: 1.5 V and 2.5 V
Number of subjects: 12
Study 10721408 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox only
Number of subjects: 45
Study 10721408 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation
Number of subjects: 45
Study 7605183 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction equation (EXP) derived from PRE group data
Number of subjects: 55
Study 7605183 — intervention group
Group type: COMPARATOR
Intervention: Validation group (VAL)
Number of subjects: 55
Study 7605183 — intervention group
Group type: COMPARATOR
Intervention: Comparison to previously published equations for clockwise ACE
Number of subjects: 55
Study 2195537 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 29
Study 2195537 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction from the central bronchial system
Number of subjects: 29
Study 96461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclazindol (100 mg/day)
Number of subjects: 0
Study 31840260 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based pediatric palliative care education
Number of subjects: 265
Study 31840260 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 265
Study 31397184 — intervention group
Group type: EXPERIMENTAL
Intervention: TIO/FORMfixed (18/12 µg once daily via Discair inhaler)
Number of subjects: 84
Study 31397184 — intervention group
Group type: EXPERIMENTAL
Intervention: TIO/FORMbid (tiotropium 18 µg by Handihaler + formoterol 12 µg twice daily by Aerolizer)
Number of subjects: 84
Study 31397184 — intervention group
Group type: COMPARATOR
Intervention: TIOmono (tiotropium 18 µg by Handihaler)
Number of subjects: 84
Study 28750854 — intervention group
Group type: EXPERIMENTAL
Intervention: DVC-LVS
Number of subjects: 228
Study 28750854 — intervention group
Group type: COMPARATOR
Intervention: USAMRIID-LVS
Number of subjects: 228
Study 25873721 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HI(I)T)
Number of subjects: 84
Study 25873721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 24016282 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy (CP)
Number of subjects: 58
Study 24016282 — intervention group
Group type: EXPERIMENTAL
Intervention: Light emitting diode phototherapy (LP)
Number of subjects: 58
Study 21266932 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice group (n = 15) - completed six additional sessions to practice a functional task (Grooved Pegboard)
Number of subjects: 23
Study 21266932 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8) - no additional practice sessions
Number of subjects: 23
Study 19181514 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal catheter anaesthesia with diamorphine 300 microg and 0.5% hyperbaric bupivacaine
Number of subjects: 34
Study 17532101 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA‐TT vaccine (Group 1)
Number of subjects: 74
Study 17532101 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal Polysaccharide Vaccine A+C (Group 2)
Number of subjects: 74
Study 17532101 — intervention group
Group type: COMPARATOR
Intervention: Tetanus Toxoid Vaccine Adsorbed (Group 3)
Number of subjects: 74
Study 14985695 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-week 2800 microg folic acid supplement
Number of subjects: 114
Study 14985695 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 400 microg folic acid supplement
Number of subjects: 114
Study 14985695 — intervention group
Group type: COMPARATOR
Intervention: Daily placebo
Number of subjects: 114
Study 15321547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford position (group O)
Number of subjects: 90
Study 15321547 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral to supine wedged position (group R)
Number of subjects: 90
Study 15321547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting to supine wedged position (group S)
Number of subjects: 90
Study 15321547 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study 9579235 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH(1‐41)/GHRH‐(1‐29)‐NH2
Number of subjects: 6
Study 9579235 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH/GHRH‐(1‐29)‐NH2
Number of subjects: 6
Study 9579235 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrocortisone/GHRH‐(1‐29)‐NH2
Number of subjects: 6
Study 9579235 — intervention group
Group type: COMPARATOR
Intervention: saline/GHRH‐(1‐29)‐NH2
Number of subjects: 6
Study 7893272 — intervention group
Group type: EXPERIMENTAL
Intervention: Legalon
Number of subjects: 7
Study 7893272 — intervention group
Group type: COMPARATOR
Intervention: Other silymarin preparations
Number of subjects: 7
Study 2491140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 78
Study 2491140 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 78
Study 2491140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 824953 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cephalosporins
Number of subjects: 93
Study 824953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 30693096 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment alongside usual IAPT care
Number of subjects: 0
Study 30693096 — intervention group
Group type: COMPARATOR
Intervention: Usual IAPT treatment alone
Number of subjects: 0
Study 29927785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 5 mg annually for 2 years
Number of subjects: 87
Study 29927785 — intervention group
Group type: COMPARATOR
Intervention: Switching from tenofovir disoproxil fumarate (TDF) to another active antiretroviral drug
Number of subjects: 87
Study 27239927 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg + ASA 300 mg (Subgroup 2)
Number of subjects: 124
Study 27239927 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 300 mg + Ticagrelor 90 mg twice daily (Subgroup 3)
Number of subjects: 124
Study 27239927 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg + ASA 300 mg (Subgroup 1)
Number of subjects: 124
Study 25336097 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation (isotonic and hypertonic solutions)
Number of subjects: 0
Study 25336097 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal aspiration with isotonic saline solution
Number of subjects: 0
Study 25336097 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic and hypertonic saline solutions
Number of subjects: 0
Study 23150927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mcg)
Number of subjects: 860
Study 23150927 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical care
Number of subjects: 860
Study 23150927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 860
Study 23150927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol and Standard surgical care
Number of subjects: 860
Study 20214777 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention based on Cognitive Behavioural Therapy (CBT)
Number of subjects: 260
Study 20214777 — intervention group
Group type: COMPARATOR
Intervention: Information-control condition
Number of subjects: 260
Study 17709365 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional coronary artery bypass grafting (Group A)
Number of subjects: 65
Study 17709365 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery (Group B)
Number of subjects: 65
Study 17709365 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting with modified, rheoparin coated cardiopulmonary bypass (Group C)
Number of subjects: 65
Study 17709365 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Conventional coronary artery bypass grafting)
Number of subjects: 65
Study 17709365 — intervention group
Group type: COMPARATOR
Intervention: Group B and C (Off-pump surgery and modified cardiopulmonary bypass)
Number of subjects: 65
Study 16330721 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based care management intervention (n = 116)
Number of subjects: 191
Study 16330721 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 75)
Number of subjects: 191
Study 12006508 — intervention group
Group type: EXPERIMENTAL
Intervention: QS-21
Number of subjects: 26
Study 12006508 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 26
Study 12006508 — intervention group
Group type: COMPARATOR
Intervention: IFA
Number of subjects: 26
Study 9667541 — intervention group
Group type: COMPARATOR
Intervention: Children's Lake Louise AMS Score (CLLS) assessed on day 4 after travel to 3488 m.
Number of subjects: 23
Study 9667541 — intervention group
Group type: COMPARATOR
Intervention: Control days (1 and 2) measurements at home and day 3 travel without altitude change to 1615 m.
Number of subjects: 23
Study 9667541 — intervention group
Group type: COMPARATOR
Intervention: Adults accompanying the children completed the Lake Louise Scoring System on days 3 and 4.
Number of subjects: 23
Study 8617554 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg daily for 5 days
Number of subjects: 64
Study 8617554 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 400 mg daily for 5 days
Number of subjects: 64
Study 8617554 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 7.5 mg/Kg thrice daily for 5 days
Number of subjects: 64
Study 8617554 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole therapy
Number of subjects: 64
Study 2765377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg or 20 mg)
Number of subjects: 0
Study 2765377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1009348 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Vivonex)
Number of subjects: 0
Study 1009348 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30252507 — intervention group
Group type: EXPERIMENTAL
Intervention: Household and caregiving activities
Number of subjects: 251
Study 30252507 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational PA
Number of subjects: 251
Study 30252507 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity PA
Number of subjects: 251
Study 28786722 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoeba system with pattern‐based addressing and injected entropy
Number of subjects: 0
Study 28786722 — intervention group
Group type: COMPARATOR
Intervention: Amoeba system without specified features
Number of subjects: 0
Study 26635296 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus messages about vaccine safety (90% of medical scientists agree vaccines are safe)
Number of subjects: 206
Study 26635296 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study 23428963 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 182
Study 23428963 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of FAQs to support peer supporters
Number of subjects: 182
Study 23428963 — intervention group
Group type: EXPERIMENTAL
Intervention: Insights gained from FAQs
Number of subjects: 182
Study 22028938 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole-cell oral cholera vaccine (OCV)
Number of subjects: 66900
Study 22028938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66900
Study 18316547 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg every other week)
Number of subjects: 463
Study 18316547 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 463
Study 18316547 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 463
Study 16735582 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered platelet-rich plasma
Number of subjects: 20
Study 16735582 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 20
Study 12898174 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced helical computed tomography (UHCT)
Number of subjects: 122
Study 12898174 — intervention group
Group type: COMPARATOR
Intervention: Intravenous urography (IVU)
Number of subjects: 122
Study 10724054 — intervention group
Group type: EXPERIMENTAL
Intervention: CAUTI (235 new cases during the study period)
Number of subjects: 1497
Study 10724054 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of 1034 patients with CAUTI (89 with >103 colony-forming units/mL)
Number of subjects: 1497
Study 10724054 — intervention group
Group type: EXPERIMENTAL
Intervention: CAUTI episodes studied (235 episodes)
Number of subjects: 1497
Study 8754444 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (group A)
Number of subjects: 463
Study 8754444 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic therapy (group B)
Number of subjects: 463
Study 8754444 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy in patients with left ventricular dysfunction
Number of subjects: 463
Study 8754444 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy in patients with symptom delay > 4 hours
Number of subjects: 463
Study 8435695 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based care (daily living programme)
Number of subjects: 189
Study 8435695 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 189
Study 3628243 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 60
Study 3628243 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 60
Study 28647136 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP (Cold Snare Polypectomy)
Number of subjects: 358
Study 28647136 — intervention group
Group type: COMPARATOR
Intervention: EMR (Endoscopic Mucosal Resection)
Number of subjects: 358
Study 28647136 — intervention group
Group type: EXPERIMENTAL
Intervention: Piecemeal resection
Number of subjects: 358
Study 28647136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EMR and CSP
Number of subjects: 358
Study 24467369 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (0, 2 or 10 mg/day/p.o.)
Number of subjects: 21
Study 24467369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 24467369 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking abstinence procedure
Number of subjects: 21
Study 22236488 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management approach including systematic screening, treatment upon positive screening, monitoring, and intensified treatment in case of non-remission.
Number of subjects: 0
Study 22236488 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 20132138 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based physical activity intervention
Number of subjects: 41
Study 20132138 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 18346028 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine (ASAQ) - artesunate 4 mg/kg daily and amodiaquine 10 mg/kg daily for 3 days.
Number of subjects: 132
Study 18346028 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL) - 5-14 kg: one tablet; 15-24 kg: two tablets; 25-34 kg: three tablets, twice daily for 3 days.
Number of subjects: 132
Study 16259789 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 600 mg reduced glutathione per day
Number of subjects: 37
Study 16259789 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 50 mg alpha‐lipoic acid per day
Number of subjects: 37